The difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network meta-analysis of randomised controlled trials of immunomodulatory kinase inhibitors
Journal
Journal of the Royal Society of Medicine
Journal Volume
11
Journal Issue
2
Pages
57-68
Date Issued
2024-02
Author(s)
Tseng, Ping-Tao
Zeng, Bing-Syuan
Hsu, Chih-Wei
Thompson, Trevor
Stubbs, Brendon
Su, Kuan-Pin
Chen, Yen-Wen
Chen, Tien-Yu
Wu, Yi-Cheng
Lin, Pao-Yen
Carvalho, Andre F
Li, Dian-Jeng
Yeh, Ta-Chuan
Sun, Cheuk-Kwan
Cheng, Yu-Shian
Shiue, Yow-Ling
Liang, Chih-Sung
Abstract
The aim of this network meta-analysis (NMA) was to assess whether participants assigned to a placebo and standard of care (SoC) group had different major coronavirus disease 2019 (COVID-19)-related outcomes than those assigned to SoC alone.
Subjects
COVID-19; Network meta-analysis; immunomodulatory kinase inhibitor; mortality; placebo
Publisher
SAGE Publications Ltd
Type
journal article